Personalized therapy in oncology: melanoma as a paradigm for molecular-targeted treatment approaches
Author:
- 27 June 2024
- journal article
- review article
- Published by Springer Nature in Clinical & Experimental Metastasis
- Vol. 41 (4) , 465-471
Abstract
In recent decades, the field of systemic cancer treatment has seen remarkable changes due to advancements in the understanding of cancer’s biology, immunology, and genetic makeup. As a result, individuals with late-stage cancers are now achieving survival rates that were previously unattainable. The goal of personalized cancer therapy is to enhance clinical outcomes by customizing drug treatments to suit the unique genetic and/or epigenetic profiles of each patient’s tumor. This approach aims to reduce the side effects commonly associated with ineffective treatments. Advances in genetic sequencing and molecular cytogenetics have been instrumental in identifying cancer-driving mutations and epigenetic irregularities, leading to the development of specific molecular therapies. This review article highlights the progress and success of targeted molecular therapies in treating malignant melanoma, illustrating the concept of personalized cancer treatment.Keywords
This publication has 61 references indexed in Scilit:
- Five-year outcomes from a phase 3 METRIC study in patients with BRAF V600 E/K–mutant advanced or metastatic melanomaEuropean Journal of Cancer, 2019
- Somatic driver mutations in melanomaCancer, 2017
- Concurrent MEK2 Mutation and BRAF Amplification Confer Resistance to BRAF and MEK Inhibitors in MelanomaCell Reports, 2013
- MEK Inhibition in the Treatment of Advanced MelanomaCurrent Oncology Reports, 2013
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trialThe Lancet, 2012
- KIT as a Therapeutic Target in Metastatic MelanomaJAMA, 2011
- Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3KCancer Cell, 2010
- Multicenter Phase II trial of high‐dose imatinib mesylate in metastatic melanomaCancer, 2006
- Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAFCell, 2004
- ErbB‐2 is a common auxiliary subunit of NDF and EGF receptors: implications for breast cancer.The EMBO Journal, 1996